ACE2 and cardiomyopathy: It was suggested that ACE2 polymorphisms may be used as novel risk markers for the left ventricular hypertrophy (LVH) in hypertensive patients (21) and ACE2 variation was indicated to be associated with risk for cardiomyopathies (22).